Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S. Oak Ridge, TN, July 27, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today an unaudited increase of 49.4% in sales of...

DAXOR CORPORATION ANNOUNCES PARTNERSHIP WITH MEDAXIOM TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®) Daxor Has Exclusive Access to the Cardiovascular Industry's Most Comprehensive and Powerful Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically...

DAXOR COMPLETES NIH FUNDED I-CORPS PROGRAM FOR COMMERCIALIZATION OF CLINICAL DECISION SUPPORT SOFTWARE Company Received Funding from NIH to Accelerate New Clinical Decision Support Software For Use With Daxor’s Blood Volume Analyzer for Heart Failure Treatment Oak Ridge, TN, July 18, 2022 (GLOBE...

DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE New BVA Device Aims to Possess Gold Standard Accuracy and Reproducibility with Increased Safety, Access, Ease of Use, and Frequency of Testing Afforded by a Non-Nuclear Tracer Oak Ridge, TN, June ...

Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 18th Annual Meeting Oak Ridge, TN, June 13, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will exhibit at the American...